Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Estrogen can cause the growth of non-small cell lung cancer cells.
Hormone therapy using fulvestrant may fight non-small cell lung cancer by lowering the amount
of estrogen the body makes. Giving erlotinib together with fulvestrant may kill more tumor
cells. It is not yet known whether giving erlotinib together with fulvestrant is more
effective than erlotinib alone in treating non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying giving erlotinib together with
fulvestrant to see how well it works compared to erlotinib alone in treating patients with
stage IIIB or stage IV non-small cell lung cancer.